Novartis completes FDA application for 'cancer-killing' technology

Cara Livernois | | Health Exec | Precision Medicine

The race to produce the first CAR-T, a technology capable of reprograming a cancer patient's white blood cells to kill tumor cells, has reached its next phase, thanks to Novartis. In Forbes, Samuele Butera, the Global Business Leader for Cell & Gene Therapies at Novartis, explains the company’s work in fighting cancer within the body.

After announcing the company had completed the application for the use of CAR-T in children with acute lymphoblastic leukemia, the company is currently waiting for a response from the Food and Drug Administration. Novartis’ application comes before that from Kite Pharmaceuticals, who announced its intention to apply in Dec. 2016.

Read the full story by clicking below: 

Novartis Makes Plans For Its Cancer-Killing T Cells

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Related Content

Pitching the business case for 3D printing labs in radiology
FDA issues first-ever clearance for OTC oximeter
Augmented reality company secures $15M in funding from Cleveland Clinic, Mayo, GE Healthcare and more
Merck to acquire Prometheus Biosciences for $10.8B
Johnson & Johnson scraps RSV vaccine after trial
Intermountain Health launches new biotech company

Around the web

AI in Healthcare
Nat’l Academy of Medicine sets ‘priorities for action’ as healthcare mulls next moves with AI

Given the precarious excitement of the moment—or is it exciting precarity?—policymakers and healthcare leaders must set directives guiding not only what to do with AI but also when to do it. 

Cardiovascular Business
Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say

The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%. 

AI in Healthcare
4 ways HHS plans to help shape a national strategy for healthcare AI

HHS has thought through the ways AI can and should become an integral part of healthcare, human services and public health. Last Friday—possibly just days ahead of seating a new secretary—the agency released a detailed plan for getting there from here.